This report was first published by Endpoints News. To see the original version, click here
Sciwind Biosciences has already licensed its GLP-1 obesity drug ecnoglutide twice over — to Pfizer and Verdiva Bio — but it is not done yet.
The Chinese biotech is seeking new partners for the rights it still holds, and data presented at the American Diabetes Association meeting could strengthen its hand.
您已阅读9%（395字），剩余91%（4139字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。